Immune Checkpoint Inhibition and Targeted Therapy and Stage IV Melanoma Survival—Reply

In Reply Uno and colleagues highlight a method to quantify the prolongation of survival using the restricted mean survival time (RMST). Based on extracted information from the published survival curves in our article, they estimated that patients in the study cohort (diagnosed 2011-2012) would survive, on average, an additional 2.0 months (95% CI, 1.3-2.7 months) compared with the historical cohort (diagnosed 2004-2008) if followed for 45 months. We used the primary data and computed the difference in RMST to be 2.2 months (95% CI, 1.5-2.9 months) if both groups were followed for 45 months. Uno and colleagues also estimated the difference in median overall survival between the groups to be 1.3 months, which is also accurate; median survival was 6.7 months (95% CI, 6.4-7.0 months) for the historical cohort vs 8.1 months (95% CI, 7.6-8.8 months) for the study cohort, a difference of 1.4 months.

https://ift.tt/2t97mFR